Trial · NCT04382586
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Respiratory Failure-free Survival | Up to Day 28 | Number of participants with respiratory failure-free survival, defined as not having died or gone into respiratory failure on or before Day 28 |
| Primary | Time to Breathing Room Air | Up to 7 months | Time to return to breathing room air is defined as the time from randomization date to the earliest time where the participant is stable on room air without supplemental oxygen. Total follow-up time in days is the total time of all participants from the randomization date to the first event date or Day 28 if there is no event. The rate was calculated as total number of events in which a participant returned to breathing room air on or before Day 28 divided by the total follow-up time in days. |
| Secondary | Number of Participants Experiencing Respiratory Failure or Death | Up to Day 28 | Number of participants experiencing respiratory failure or death on or before Day 28 |
| Secondary | Number of Participants With All-cause Mortality | Up to Day 28 | Number of participants with all-cause mortality on or before Day 28 |
| Secondary | Number of Participants Discharged Alive | Up to Day 28 | Number of participants discharged alive on or before Day 28 |
| Secondary | Number of Participants Discharged Alive From the ICU | Up to Day 28 | Number of participants discharged alive from the intensive care unit (ICU) on or before Day 28 |
| Secondary | Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale | Up to Day 28 | Number of participants with improvement in WHO 8-point-scale, in which improvement was considered a score that changed from ≥4 at baseline to ≤ 3 at Day 28 as assessed by the investigator. Scoring ranges from 0 = uninfected with no clinical or virologic evidence of disease to 8 = dead. |
| Secondary | Duration of Mechanical Ventilation | Up to Day 28 | Number of days on mechanical ventilation on or before Day 28 |
| Secondary | Duration of Hospitalization | Up to Day 28 | Number of days hospitalized on or before Day 28 |
| Secondary | PaO2:FiO2 Ratio | Baseline, Day 7, Day 14, Day 21 and Day 28 | Partial pressure of oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio |
| Secondary | Number of Participants With Adverse Events | Up to 7 months | Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), treatment-related adverse events (AEs), and TEAEs grade 3 or higher, including laboratory findings |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04382586/registered